Search This Blog

Monday, July 2, 2018

Neurotrope Has Additional Phase 2 Data at Alzheimer’s Association Conference


Neurotrope Inc. (NASDAQ: NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), is announcing the acceptance of a presentation at the Alzheimer’s Association International Conference 2018 (AAIC) being held in Chicago, from July 22-26, 2018.
    Title Significant Cognitive Improvement with Bryostatin
          for Advanced Alzheimer's

          Patients in the Absence of Memantine (Poster
          presentation Abstract #27295)


    Developing Topics Session: P4-199:

    Date/Time                  Wednesday, July 25, 2018: 9:30 AM-
                                4:15 PM

    Location Hall              F1 - McCormick Place
“The primary mechanisms of action (MOAs) of bryostatin, Neurotrope’s lead compound to treat Alzheimer’s disease (AD) neurodegeneration, are synaptogenesis and anti-apoptosis: the generation of new, mature synaptic connections and the prevention of neuronal death. This has been demonstrated in pre-clinical models because our target PKC epsilon activates synaptic growth factors like BDNF, NGF and IGF-1. Our most recent comprehensive data analyses, to be reported at AAIC 2018, have demonstrated that advanced AD patients show improvement (> 6.0 points vs. placebo and baseline) in the Severe Impairment Battery (SIB) even 30 days after all drug dosing has been completed in patients not on memantine. The data indicate that PKC’s synaptogenesis efficacy cannot occur when the NMDA receptor is blocked. Data from many other laboratories over the years implicating NMDA in memory processing could now take on new meaning from Neurotrope’s clinical results with bryostatin – in the absence of memantine. We are excited to be presenting this new data at this prestigious international forum” stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.